GTAB B Stock Overview
A medical technology company, engages in the development, production, and sale of products for use in organ transplantation. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Glycorex Transplantation AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.16 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.20 |
| 1 Month Change | 54.90% |
| 3 Month Change | 119.44% |
| 1 Year Change | 144.96% |
| 3 Year Change | -60.99% |
| 5 Year Change | -79.41% |
| Change since IPO | -24.76% |
Recent News & Updates
Shareholder Returns
| GTAB B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0.3% | 5.8% | 1.1% |
| 1Y | 145.0% | 5.1% | 14.0% |
Return vs Industry: GTAB B exceeded the Swedish Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: GTAB B exceeded the Swedish Market which returned 13.5% over the past year.
Price Volatility
| GTAB B volatility | |
|---|---|
| GTAB B Average Weekly Movement | 24.5% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: GTAB B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: GTAB B's weekly volatility has increased from 19% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 20 | Johan Nilsson | www.glycorex.se |
Glycorex Transplantation AB (publ), a medical technology company, engages in the development, production, and sale of products for use in organ transplantation. It develops a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood focusing areas within transplants, blood transfusion, and blood products, as well as autoimmune disease. The company’s principal product is Glycosorb-ABO, which facilitates the transplantation of organs over the blood group barriers that is used for the blood group-incompatible kidney, liver, heart, lungs, pancreatic, and stem cells transplantation procedures.
Glycorex Transplantation AB (publ) Fundamentals Summary
| GTAB B fundamental statistics | |
|---|---|
| Market cap | SEK 229.69m |
| Earnings (TTM) | -SEK 25.54m |
| Revenue (TTM) | SEK 32.32m |
7.2x
P/S Ratio-9.1x
P/E RatioIs GTAB B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTAB B income statement (TTM) | |
|---|---|
| Revenue | SEK 32.32m |
| Cost of Revenue | SEK 5.65m |
| Gross Profit | SEK 26.66m |
| Other Expenses | SEK 52.20m |
| Earnings | -SEK 25.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 82.51% |
| Net Profit Margin | -79.03% |
| Debt/Equity Ratio | 1.9% |
How did GTAB B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 06:55 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Glycorex Transplantation AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|